Seroprevalence and determinants of SARS-CoV-2 anti-nucleocapsid IgG in a vaccinated Iranian adult population: A cross-sectional study, Summer 2023.

ABSTRACT: Anti-nucleocapsid (anti-N) IgG serology is increasingly used to distinguish natural SARS-CoV-2 infection from vaccine-induced immunity. However, post-vaccination seroepidemiological data from highly immunized Middle Eastern populations remain limited. We assessed anti-N IgG seroprevalence and its predictors in a cohort of Iranian adults during the summer of 2023. A total of 251 individuals aged 18-65 years were enrolled through community outreach at Gholhak Laboratory, a high-throughput diagnostic center in Tehran. Participants completed structured questionnaires that captured demographic characteristics, COVID-19 vaccination history (vaccine platform, dose count, and time since last dose), smoking status, occupation, pregnancy status, and prior COVID-19-related hospitalization. Anti-N IgG

SUBMITTER: Yeganeh A 

PROVIDER: S-EPMC12445513 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature